The diabetes drug Januvia, created by Merck and Co, has been shown to substantially improve blood sugar levels over two years of treatment in combination with the older drug metformin. Januvia was found to be well tolerated on the whole.
Januvia, which is also known as sitaglipti, is a blockbuster drug for the company, and occupies a unique position in the market as the only DPP-4 inhibitor. Annual sales of the drug now exceed $1.6 billion.
Further studies, which were presented at the European Association for the Study of Diabetes annual conference in Romen, demonstrated that the drug was safe and effective. The news of long term blood sugar level improvement is particularly important for people with type 2 diabetes .
Diabetes expert Bernard Charbonnel of University Hospital in Naples, France, was reported in the news as commenting: “This is important for patients and physicians because type 2 diabetes is characterized by a progressive deterioration in beta cell function over time, resulting in the disease worsening. This progression of disease leads to decreased effectiveness of all known treatments over time, with patients often requiring multiple therapies in order to achieve their glycaemic goals.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…